Article
Oncology
Khalid W. Kalim, Jun-Qi Yang, Mark Wunderlich, Vishnu Modur, Phuong Nguyen, Yuan Li, Ting Wen, Ashley Kuenzi Davis, Ravinder Verma, Qing Richard Lu, Anil G. Jegga, Yi Zheng, Fukun Guo
Summary: Targeting Cdc42 in Treg cells has shown promising therapeutic potential in cancer immunotherapy, by enhancing antitumor T-cell immunity without triggering autoimmune reactions. This approach involves inducing Treg cell instability through Cdc42 targeting, leading to improved immune responses against tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Multidisciplinary Sciences
Alba Rodriguez-Garcia, Rachel C. Lynn, Mathilde Poussin, Monika A. Eiva, Lauren C. Shaw, Roddy S. O'Connor, Nicholas G. Minutolo, Victoria Casado-Medrano, Gonzalo Lopez, Takami Matsuyama, Daniel J. Powell
Summary: The study demonstrates that targeting FR beta-expressing TAMs with CAR-T cells can enhance antitumor immune responses and improve the efficacy of adoptive T-cell therapy in pre-clinical models.
NATURE COMMUNICATIONS
(2021)
Review
Immunology
Juan Mi, Qing Ye, Yuanzeng Min
Summary: CAR-T therapy has achieved success in hematologic tumors, but its efficacy in solid tumors is limited. Challenges in locating, inhibiting, and promoting survival of CAR-T cells in solid tumors exist. Nanotechnology has potential to improve the therapeutic effect of solid tumors by modifying CAR-T cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Wei Yin, Yihong Li, Yan Song, Jiarui Zhang, Chao Wu, Yu Chen, Ying Miao, Changdong Lin, Yuli Lin, Dapeng Yan, Jianfeng Chen, Rui He
Summary: CCRL2 plays a crucial role in activating immunostimulatory macrophages, enhancing antitumor T-cell responses and promoting tumor rejection. Its deficiency leads to impaired macrophage activation and aggravated tumor growth, highlighting CCRL2 as a potential biomarker and therapeutic target for cancer immunotherapy.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Immunology
Yatong Chen, Jing Xu, Xiaodong Wu, Hui Yao, Zhou Yan, Ting Guo, Wenjing Wang, Peixiao Wang, Yu Li, Xiangmin Yang, Hao Li, Huijie Bian, Zhi-Nan Chen
Summary: Deletion of CD147 in T cells limits tumor growth in mouse melanoma and lung cancer. CD147 is upregulated in CD8(+) TILs and coexpressed with immune-checkpoint molecules, leading to increased antitumor responses and potential as a target for cancer immunotherapy.
CELLULAR & MOLECULAR IMMUNOLOGY
(2021)
Review
Immunology
Jiaqi Huang, Jie Zhang, Zhengyang Guo, Chen Li, Zhen Tan, Junjie Wang, Jianling Yang, Lixiang Xue
Summary: EZH2 is the catalytic subunit of PRC2, regulating gene expression by trimethylation of H3 lysine 27, and is associated with various cancers. Studies indicate that EZH2 may also regulate T cell development, differentiation, and function, impacting immune homeostasis.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Brett A. Schroeder, Natalie A. LaFranzo, Bonnie J. LaFleur, Rachel M. Gittelman, Marissa Vignali, Shihong Zhang, Kevin C. Flanagan, Julie Rytlewski, Laura Riolobos, Brian C. Schulte, Teresa S. Kim, Eleanor Chen, Kimberly S. Smythe, Michael J. Wagner, Jose G. Mantilla, Jean S. Campbell, Robert H. Pierce, Robin L. Jones, Lee D. Cranmer, Seth M. Pollack
Summary: In dedifferentiated liposarcoma (DDLPS), high TCR clonality combined with low T-cell fraction predicts worse outcomes, while CD4+ T-cell infiltration is associated with better outcomes; CD14+ monocytes and M2 macrophages are associated with worse outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Ingunn M. Stromnes, Ayaka Hulbert, Meagan R. Rollins, Ryan S. Basom, Jeffrey Delrow, Patrick Bonson, Adam L. Burrack, Sunil R. Hingorani, Philip D. Greenberg
Summary: This study investigates the role of immune checkpoints in mediating functional dysfunction of engineered T cells in pancreatic ductal adenocarcinoma (PDA). The findings suggest that blockade of PD-1 signaling alone is not enough to overcome the dysfunction of TCR engineered T cells in PDA. Contributions from both the differentiation pathways induced during the T cell engineering process and intratumoral suppressive mechanisms render engineered T cells dysfunctional.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Xiuting Liu, Graham D. Hogg, David G. DeNardo
Summary: The success of checkpoint inhibitors in cancer treatment has highlighted the importance of the immune system, particularly in eliciting antitumor responses. While initially thought to primarily target T cells, recent research suggests that these inhibitors may also impact innate immunity, thus playing a significant role in clinical efficacy. Further investigation into the mechanisms of action of checkpoint therapies on innate antitumor responses is crucial for developing effective combination treatments to combat checkpoint resistance in refractory malignancies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Cangang Zhang, Lei Lei, Xiaofeng Yang, Kaili Ma, Huiqiang Zheng, Yanhong Su, Anjun Jiao, Xin Wang, Haiyan Liu, Yujing Zou, Lin Shi, Xiaobo Zhou, Chenming Sun, Yuzhu Hou, Zhengtao Xiao, Lianjun Zhang, Baojun Zhang
Summary: The study found that old mice have a higher proportion of cytotoxic CD8(+) T cells, naturally occurring Tregs, among other immune cells in their tumors, while young mice have a higher percentage of exhausted CD8(+) T cells, induced Tregs, among others.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Gastroenterology & Hepatology
Xinhai Zhu, Ke Li, Guichao Liu, Ruan Wu, Yan Zhang, Siying Wang, Meng Xu, Ligong Lu, Peng Li
Summary: Recent studies have shown that gut microbiota and their metabolites can modulate the antitumor immunity of immune cells, but the underlying mechanisms are unclear. This study found that the serum level of butyric acid is correlated with the expression of PD-1 on CD8(+) and V?9 Vd2 T cells in patients with NSCLC. Patients who responded to anti-PD-1 therapy had higher levels of acetic acid, propionic acid, and butyric acid. Depletion of gut microbiota decreased butyrate levels in feces and serum of tumor-bearing mice.
Article
Medicine, Research & Experimental
Yujun Lin, Cheng Cui, Min Su, Lawrence K. Silbart, Haiyan Liu, Jin Zhao, Lang He, Yuanmao Huang, Dexin Xu, Xiaodan Wei, Qian Du, Laijun Lai
Summary: TAPBPL is a novel T cell co-inhibitory molecule that inhibits the proliferation, activation, and cytokine production of T cells, and has the potential to be used for the treatment of cancer, infections, autoimmune diseases, and transplant rejection.
EMBO MOLECULAR MEDICINE
(2021)
Review
Immunology
Van To, Vera J. Evtimov, Graham Jenkin, Aleta Pupovac, Alan O. Trounson, Richard L. Boyd
Summary: CAR-T therapy has shown remarkable outcomes for B cell malignancies but its application in treating T cell lymphoma, specifically CTCL, is limited. Overcoming the barriers and challenges in CAR-T cell therapy for CTCL, such as T cell aplasia, contamination, fratricide, and tumor heterogeneity, by using innovative CAR engineering to target multiple antigens is necessary.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Jang Hyun Park, Hyun-Jin Kim, Chae Won Kim, Hyeon Cheol Kim, Yujin Jung, Hyun-Soo Lee, Yunah Lee, Young Seok Ju, Ji Eun Oh, Sung-Hong Park, Jeong Ho Lee, Sung Ki Lee, Heung Kyu Lee
Summary: Glioblastoma presents a hypoxic microenvironment that affects gamma delta T cell-mediated antitumor immune responses. The tumor's high demand for oxygen leads to suppression of gamma delta T cell function, which can be alleviated by reducing hypoxia. This study highlights the importance of gamma delta T cells in antitumor immunity against brain tumors.
Article
Biology
Emily R. Webb, Georgia L. Dodd, Michaela Noskova, Esme Bullock, Morwenna Muir, Margaret C. Frame, Alan Serrels, Valerie G. Brunton
Summary: The over-expression of Kindlin-1 in breast cancer is associated with metastasis-free survival, but the mechanisms are poorly understood. This study reveals that Kindlin-1 promotes immune evasion in breast cancer mouse models. Deletion of Kindlin-1 led to tumor regression and reduced tumor infiltrating Tregs, which was associated with increased IL-6 secretion. Conditioned media from Kindlin-1-depleted cells resulted in decreased suppression of CD8(+) T cells by Tregs, dependent on IL-6.